An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming
Competitors in the field of adalimumab and insulin products may soon include authorized biologics.
top of page
Subscriber login:
SUBMIT
Remember me
Search
- Oct 22, 2021
AMCP Nexus 2021: A Wrap-Up
Biosimilar adoption and biosimilar market share were among the featured topics at the AMCP Nexus 2021 meeting in Denver, Colorado.
- Oct 21, 2021
AMCP Nexus 2021: Biosimilars Are Gathering Momentum — and Interchangeability May Not Matter
IPD Analytics discussed biosimilar uptake as both biosimilar market share and adoption of biosimilars become more prominent.
- Apr 20, 2021
Further Dissecting the Launch of Adalimumab Biosimilars in the US
According to the IPD Analytics team, an adalimumab biosimilar launch may occur as early as late 2022.
- Apr 20, 2021
National Trends in Prescription Drug Expenditures and Projections for 2021
Pharmaceutical expenditure was looked at in this study using IPD Analytics pipeline drug data as a source to predict future potential growth
- Oct 8, 2020
EY Announces Howard Krass of IPD Analytics, LLC as Entrepreneur Of The Year® 2020 Winner
Ernst and Young announced Howard Krass of IPD Analytics was named an Entrepreneur of the Year® 2020 Florida Award winner.
- May 15, 2020
Will COVID-19 Clog Generics, Biologics Pipeline?
IPD Analytics experts discussed the impact of Covid-19 on the drug pipeline.
- Apr 29, 2020
IPD Analytics Experts Discuss Humira's Influence on Biosimilars
IPD Analytics experts discussed biosimilar competition on MJH Life Sciences News Network
- Apr 26, 2020
IPD Analytics Experts Discuss the Insulin Pipeline
With conversion of the BLA pathway, new launches may receive interchangeability. New insulin products are being launched in the near future
- Apr 22, 2020
Drug Pipeline for 2020 Strong in Generics, Biosimilars
According to interviewed experts at IPD Analytics, the 2020 drug pipeline includes a large number of generic launches.
- Apr 20, 2020
A Look at the Generic and Biosimilar Drug Pipeline
IPD Analytics discussed both the generic and biosimilar drugs coming to market, and implications for managed care pharmacy at AMCP eLearning
- Apr 20, 2020
AMCP Presenters Predict 4 More Biosimilar Launches in 2020
The pace of clinical trials have been affected by COVID-19, according to IPD Analytics' experts on the pharmaceutical pipeline.
- Jan 23, 2020
Express Scripts Coverage, FDA Label Update Boost Rybelsus
There is some difference in opinion regarding how payers will set their formulary management strategy on GLP-1's.
- Aug 12, 2019
Q&A, Part II: How Payers and Providers are Responding to the Biosimilar Market
Experts from IPD Analytics discuss payer management of biosimilars in the U.S. market.
- Aug 5, 2019
Q&A: What Providers Need to Know About a Changing Biosimilar Market
In this Q&A from Advisory Board, IPD Analytics' experts discussed what providers need to know about the U.S. biosimilar market.
- Aug 1, 2019
National Trends in Prescription Drug Expenditures and Projections for 2019
Pharmaceutical expenditure was looked at in this study using IPD Analytics pipeline drug data as a source to predict future potential growth
- May 9, 2019
ICER, IPD Announce New Analytics Partnership
IPD Analytics and ICER are collaborating to enhance drug pricing transparency.
bottom of page